Czech immuno-oncology firm SOTIO has acquired the rights to USA-based Unum Therapeutics’ (Nasdaq: UMRX) BOXR cell therapy platform and lead T cell therapy programs.
Based in Prague, SOTIO is owned by PPF Group, and is focused on the development of immuno-oncology treatments for solid cancers.
Unum’s proprietary Bolt-on Chimeric Receptor technology incorporates novel transgenes to enhance T cell function in the solid tumor microenvironment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze